rosiglitazone has been researched along with Orbital Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feldon, SE; Guo, N; Phipps, RP; Woeller, CF | 1 |
1 other study(ies) available for rosiglitazone and Orbital Diseases
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.
Topics: Cell Adhesion; Cells, Cultured; Fibroblasts; Fibrosis; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Hypoglycemic Agents; Inflammation; Ligands; Orbit; Orbital Diseases; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Transforming Growth Factor beta | 2011 |